GeneSys Biologics
GeneSys Biologics is a privately held, Hyderabad-based biosimilar development company founded in 2014, staffed by a team of 51–100 with global biosimilars experience and funded by ~$5.28M across four rounds through April 2017.
- Company typePrivate
- Founded2014
- HeadquartersHyderabad, India
- Headcount51–100
- GTM typeB2B
- OfferingServices
What GeneSys Biologics does
GeneSys Biologics is a privately held biosimilar development company founded in 2014 and headquartered in Hyderabad, India. According to the firm's self-description, it comprises individuals with strong global experience in the development of biosimilars, positioning it as a specialized biopharmaceutical R&D organization rather than a diversified life-sciences operator. The company is reported to have 51–100 employees, consistent with a mid-stage biotech operating analytical characterization, cell-line, and process-development functions typical of biosimilar programs.
The company's website (genesysbiologics.com) was not accessible during data collection — it returned only a verification/loading page — and the source data provides no further detail on its specific biosimilar pipeline, target molecules, intellectual property, regulatory filings, manufacturing footprint, or strategic partners. As a result, the precise therapeutic areas (e.g., oncology biologics, immunology, insulin/insulin analogs, mAbs), development stage, and geographic markets it targets cannot be confirmed from the available evidence.
GeneSys Biologics' revenue model and business model are not disclosed in the input data. No customers, pricing, contract structures, or licensing/out-licensing arrangements are reported. The company's capital history consists of four disclosed funding rounds between April 2015 and April 2017 totaling approximately $5.28 million from undisclosed investors, suggesting an early- to mid-stage R&D funding profile typical of pre-commercial biosimilar developers; no subsequent capital events are on record, leaving the company's current commercial status and revenue mechanics undetermined.
GeneSys Biologics firmographics
Firmographics- Name
- GeneSys Biologics
- Website
- https://genesysbiologics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- GeneSys Biologics is a privately held, Hyderabad-based biosimilar development company founded in 2014, staffed by a team of 51–100 with global biosimilars experience and funded by ~$5.28M across four rounds through April 2017.
- Ownership category
- akta.pro rank
GeneSys Biologics industry classification
Industry- Product category
- Biosimilar Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance) (HLAAAHAJ)
- akta.pro secondary industries
- Recombinant Protein Biosimilars (hormones, enzymes, cytokines) (HLAAAHAB), Biosimilar Manufacturing & Fill-Finish (drug substance/drug product, device integration) (HLAAAHAK), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
Keywords
Where GeneSys Biologics is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Markets served
GeneSys Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
GeneSys Biologics product offering
Product offeringCore offering
GeneSys Biologics is focused on the development of biosimilars, drawing on a team with global experience in this field. The company works in the biopharmaceutical space around follow-on biologic drugs, with detailed product pipeline and service offerings not disclosed in the available source data.
Differentiator
Problem solved
Functional benefit
Companies that use GeneSys Biologics
Customer profileIdeal customer profiles1 record
GeneSys Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GeneSys Biologics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
GeneSys Biologics competitors and assessment
Company assessmentEmerging players
- Syngene International: Syngene provides contract research, development, and biologics manufacturing services from India, comparable in its CRO/CDMO-like services component of GeneSys's potential business model.
Broad incumbents
- Dr. Reddy's Laboratories: Dr. Reddy's operates a global biosimilars and generics business with biosimilars in oncology and immunology, comparable in product category to GeneSys but at substantially larger scale with global commercialization.
- Zydus Cadila (Zydus Lifesciences): Zydus has an active biosimilars pipeline (adalimumab, trastuzumab) and operates from India with global regulatory ambitions, comparable in category to GeneSys though with much greater scale.
- Aurobindo Pharma: Aurobindo has expanded into biosimilars via its subsidiaries and is investing in biologics manufacturing capacity. Comparable product category to GeneSys with a broader generics base providing scale advantages.
- Biocon Limited: Biocon is India's largest and most diversified biosimilars developer with multiple approved products (trastuzumab, bevacizumab, insulin glargine) globally. It is the closest large-scale domestic comparable to GeneSys's stated biosimilars development focus.
Direct peers
- Intas Pharmaceuticals: Intas, through its Accord and other subsidiaries, develops and markets biosimilars including rituximab, trastuzumab, and pegfilgrastim across regulated and emerging markets. Highly comparable in biosimilars development focus to GeneSys.
- Enzene Biosciences: Enzene is an India-based biologics CDMO and biosimilars developer offering process development, manufacturing, and biosimilar products, highly comparable to GeneSys in offering biosimilars development services with India cost base.
- Mabxience: Mabxience is a biosimilars-focused developer with manufacturing in Spain and Argentina, developing rituximab, bevacizumab, and trastuzumab biosimilars. Comparable as a focused biosimilars specialist pursuing emerging and regulated market approvals.
- Alvotech: Alvotech is a pure-play biosimilars developer with a pipeline of monoclonal antibody biosimilars and approved assets in global markets, including India through partners. It mirrors GeneSys's focused biosimilars strategy with global ambitions.
Regional players
- Reliance Life Sciences: Reliance Life Sciences develops biosimilars (rituximab, bevacizumab, trastuzumab) primarily for India and emerging markets. Directly comparable in India-based biosimilars development activities to GeneSys.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
GeneSys Biologics social profiles
Digital presenceGeneSys Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneSys Biologics leadership team
Management profileNumber of profiles
GeneSys Biologics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneSys Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneSys Biologics
What does GeneSys Biologics do?
GeneSys Biologics is focused on the development of biosimilars, drawing on a team with global experience in this field. The company works in the biopharmaceutical space around follow-on biologic drugs, with detailed product pipeline and service offerings not disclosed in the available source data.
Is GeneSys Biologics a public or private company?
GeneSys Biologics is a private company. It is classified as unknown and is currently operating.
When was GeneSys Biologics founded?
GeneSys Biologics was founded in 2014. It employs 51 to 100 people.
Where is GeneSys Biologics based?
GeneSys Biologics is headquartered in Hyderabad, India, in the Asia region.
Who are GeneSys Biologics's main competitors?
Syngene International is listed as an emerging player. Broad incumbents are Dr. Reddy's Laboratories, Zydus Cadila (Zydus Lifesciences), Aurobindo Pharma and Biocon Limited. Direct peers are Intas Pharmaceuticals, Enzene Biosciences, Mabxience and Alvotech. Reliance Life Sciences is listed as a regional player.
Does GeneSys Biologics have an API?
No public API is recorded for GeneSys Biologics.
What industry is GeneSys Biologics in?
GeneSys Biologics's product category is Biosimilar Development. Its primary akta.pro industry code is HLAAAHAJ, Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance), with a secondary code of HLAAAHAB, Recombinant Protein Biosimilars (hormones, enzymes, cytokines). Its NAICS code is 541714 and its SIC code is 2836.